Posted by Michael Wonder on 12 Apr 2018
Mallinckrodt shares slide on whistleblower lawsuit involving its best-selling drug
12 April 2018 - The lawsuit filed by Rasvinder Dhaliwal, former associate director at Mallinckrodt, claims the company didn't know what was in its best-selling drug Acthar despite continuing to raise the price.
Mallinckrodt Pharmaceuticals shares slid nearly 7% on news of a whistleblower lawsuit involving its best-selling drug, Acthar.
In the suit, Rasvinder Dhaliwal, former associate director at Mallinckrodt, claims the company continued to raise the price of the blockbuster medicine without knowing what was in it. She also alleges Accredo Health, a mail-order pharmacy unit of Express Scripts, was involved in pricing the drug.
